Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will discuss the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and highlight Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
Annovis Bio is focused on developing treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Buntanetap (formerly posiphen) is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The presentation at Fierce Biotech Week underscores the industry’s growing interest in multi-target approaches for complex neurodegenerative diseases. Annovis’ strategy of targeting several toxic proteins at once could represent a paradigm shift in Alzheimer’s treatment, which has historically focused on single protein targets. If successful, buntanetap may offer a more comprehensive therapeutic option for patients, potentially slowing or stopping disease progression.
For more information about Annovis Bio, visit the company’s website at www.annovisbio.com. The full press release is available at https://ibn.fm/kZ2Z4. Latest news and updates regarding ANVS can be found in the company’s newsroom at https://ibn.fm/ANVS.
